We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.00 | 5.80% | 18.25 | 17.50 | 19.00 | 18.25 | 17.75 | 17.75 | 215,337 | 08:24:48 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.43 | 16.64M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/8/2020 11:45 | so raytard you say 51k for the year even though they sold 120k boxes in january lol | manc10 | |
19/8/2020 11:44 | rayrac - as I suspect you know, there are umpteen flaws in your H&B sales calculation. 1) You're only looking at one Slimbiome flavour, whereas H&B sells three. 2. You're only taking into account online sales. H&B also has over 700 physical shops in the UK alone (all currently open & selling). 3) August is traditionally a very slow month for retail. It also won't be one of the stronger months for a product like Slimbiome. So basing annual figures on this is just plain daft. 4) Any retailer's calls to action - including alleged sales within the past 48 hours - are only as good as the data. And only the retailer knows this data. So they could be overstating things. All told, this makes any attempt at estimating annual sales pointless, as there are simply too many unknowns. | lord loads of lolly | |
19/8/2020 11:42 | no like me in your nightmares | manc10 | |
19/8/2020 11:41 | Royalties 100%?! Yes, in your dreams! | rayrac | |
19/8/2020 11:20 | so i think they have sold around 500k and optis royalties are 100% profit come on ray slarty told you around the area he thinks we know with elrics conversation with soh that its nearer to elrics estimate of 4.40 than tws at 1.35 so slit the difference and be conservative at ,2.50 you do the maths he reached 4.40 on normal retail margins 500k x 2.50 very conservative thats one revenue stream out of 40 , another the online opti shop i estimate 5k orders years end so say 75 quid an order again do the maths , and that is only 2 revenue streams out of 40 5000 x 75 quid | manc10 | |
19/8/2020 11:18 | manc10 redone link a product with lpldl in it going on television in taiwan | humphries1 | |
19/8/2020 11:08 | Anyway, I thought you were on yer bike?! | rayrac | |
19/8/2020 11:04 | Look at H&b web site...14 sold x £19.99 = £280 in last 48 hrs. 365 days div by 2 = 184.5 x £280 = £51k? Isn’t much for a £50m mc company? And H&B take their cut out of that. | rayrac | |
19/8/2020 10:46 | htT ps://www.youtube.com | manc10 | |
19/8/2020 10:33 | so i think they have sold around 500k and optis royalties are 100% profit come on ray slarty told you around the area he thinks we know with elrics conversation with soh that its nearer to elrics estimate of 4.40 than tws at 1.35 so slit the difference and be conservative at ,2.50 you do the maths he reached 4.40 on normal retail margins 500k x 2.50 very conservative thats one revenue stream out of 40 , another the online opti shop i estimate 5k orders years end so say 75 quid an order again do the maths , and that is only 2 revenue streams out of 40 5000 x 75 quid | manc10 | |
19/8/2020 10:22 | more lies 14/10/16 yesterday was 204 | manc10 | |
19/8/2020 10:21 | I make that £51,000 turnover per year. And that’s h&bs Own label, so what do Opti get out of it?!! | rayrac | |
19/8/2020 10:15 | H & b sold 14 packets of Slimbiome in last 2 days. Ffs | rayrac | |
19/8/2020 10:14 | Make you fat and sure way to prostate cancer! 👉🏾 But enjoy! | rayrac | |
19/8/2020 10:06 | anyway off out for some realale | manc10 | |
19/8/2020 09:55 | Is that all?! | rayrac | |
19/8/2020 09:52 | slimbiome the top seller at h and b numero uno on there website | manc10 | |
19/8/2020 09:48 | Researchers with the Snyder Institute for Chronic Diseases at the Cumming School of Medicine (CSM) have discovered which gut bacteria help our immune system battle cancerous tumours and how they do it. The discovery may provide a new understanding of why immunotherapy, a treatment for cancer that helps amplify the body's immune response, works in some cases, but not others. The findings, published in Science, show combining immunotherapy with specific microbial therapy boosts the ability of the immune system to recognize and attack cancer cells in some melanoma, bladder and colorectal cancers. Dr. Kathy McCoy, PhD, is a leading expert on the body's relationship with the microbiome. She and her team are focused on harnessing the power of the microbiome to improve health and treat diseases. McCoy says to harness and direct that power scientists need to better understand the role bacteria play in regulating the immune system. "Recent studies have provided strong evidence that gut microbiota can positively affect anti-tumour immunity and improve the effectiveness of immunotherapy in treating certain cancers, yet, how the bacteria were able to do this remained elusive, " says McCoy, director of the International Microbiome Centre at the University of Calgary and principal investigator on the study. "We've been able to build on that work by showing how certain bacteria enhance the ability of T-cells, the body's immunity soldiers that attack and destroy cancerous cells." First, the researchers identified bacterial species that were associated with colorectal cancer tumours when treated with immunotherapy. Working with germ-free mice, they then introduced these specific bacteria along with immune checkpoint blockade, a type of cancer immunotherapy. Research revealed that specific bacteria were essential to the immunotherapy working. The tumours shrank, drastically. For those subjects that did not receive the beneficial bacteria, the immunotherapy had no effect. "We found that these bacteria produce a small molecule, called inosine," says Dr. Lukas Mager, MD, PhD, senior postdoctoral researcher in the McCoy lab and first author on the study. "Inosine interacts directly with T-cells and together with immunotherapy, it improves the effectiveness of that treatment, in some cases destroying all the colorectal cancer cells." The researchers then validated the findings in both bladder cancer and melanoma. The next step in this work will be to study the finding in humans. The three beneficial bacteria associated with the tumours in mice have also been found in cancers in humans. "Identifying how microbes improve immunotherapy is crucial to designing therapies with anti-cancer properties, which may include microbials," says McCoy. "The microbiome is an amazing collection of billions of bacteria that live within and around us everyday. We are in the early stage of fully understanding how we can use this new knowledge to improve efficacy and safety of anti-cancer therapy and improve cancer patient survival and well-being." | manc10 | |
19/8/2020 09:26 | i know everything | manc10 | |
19/8/2020 09:26 | woooooooooooooooooow lool | manc10 | |
19/8/2020 09:24 | Don’t worry, I know where you reside.👉 | rayrac |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions